Anti-MUC1 [CD-1] Antibody

This IgG1 kappa antibody was generated against recombinant human MUC1-C cytoplasmic domain (MUC1-CD) and recognizes an epitope (NYGQLDIFP) between amino acids 7 and 15.

Anti-MUC1 (CD-1) is ideal for Western Blot (WB) and Immunoprecipitation (IP) experiments.

Mucin 1 (MUC1) is aberrantly overexpressed in diverse human carcinomas and certain hematologic malignancies, and is an attractive target for drug development. MUC1 consists of two subunits; the MUC1 C-terminal (MUC1-C) subunit is an oncoprotein and cancer target. The MUC1-C subunit contains an extracellular domain, a transmembrane region, and a cytoplasmic domain. The MUC1-C cytoplasmic domain (CD) has been shown to interact with effectors such as PI3K, NF-kappaB, and Beta-Catenin which have all been linked to transformation. The MUC1-C cytoplasmic domain also contains a CQC motif necessary for dimerization, interaction with effectors, and nuclear localization. Cell-penetrating peptides and small molecules have been designed to block this site, one of which is currently in Phase I clinical evaluation. As vaccines and drugs are well under development against MUC1, antibodies will serve as useful biomarkers to define those patients who express MUC1-C and are thus likely to respond.

From the laboratory of Donald W. Kufe, MD, Dana-Farber Cancer Institute.

The Investigator's Annexe Part of The Investigator's Annexe program.

Catalog Number Product Size AVAILABILITY Price Qty
EDF001
Anti-MUC1 [CD-1] Antibody
100ug 3-5 weeks
Regular Price:$393.00
Specifications

Product Type: Antibody
Antigen: Muc1-Cytoplasmic Domain (MUC1-CD)
Isotype: IgG1 kappa
Clonality: Monoclonal
Clone Name: CD-1
Reactivity: Human
Immunogen: Purified protein
Species Immunized: Mouse
Epitope: NYGQLDIFP
Purification Method: Affinity chromatograpy
Method Used to Determine Concentration: Nanodrop
Buffer: PBS
Tested Applications: WB, IP
Concentration: 1mg/mL
Storage: 4C (working) -20C or -80C (stock)
Shipped: Cold packs

Data

Immunoblot and immunoprecipitation analyses with anti-MUC1-CD.

(A) Schematic of oncogenic MUC1-Csubunit with the 58 aa extracellular domain (ED), the 28 aatransmembrane region (TM), and the 72 aa cytoplasmic domain(CD). Highlighted are the sites for N-glycosylation inthe ED and for anti-MUC1-CD binding in the CD. (B) Lysatesfrom the indicated cell lines were immunoblotted withanti-MUC1-CD and anti-b-actin. (C) Lysates from MCF-7cells were immunoprecipitated with anti-MUC1-CD or, as acontrol, IgG. The precipitates were immunoblotted with anti-MUC1-CD. 

Adapted from: Panchamoorthy G, Rehan H, Kharbanda A, Ahmad R, Kufe, D. A monoclonal antiboyd against the oncogenic mucin 1 cytoplasmic domain. Hybridoma, 30(6):531-535 (2011).

Provider
From the laboratory of Donald W. Kufe, MD, Dana-Farber Cancer Institute.
Comments

The extracellular domain is subject to glycosylation at the third asparagine residue. As such, MUC1-C in cell lysates is detectable as a broad 20-25 kDa glycosylated form.

References
  1. Panchamoorthy G, Rehan H, Kharbanda A, Ahmad R, Kufe, D. A monoclonal antiboyd against the oncogenic Mucin 1 cytoplasmic domain. Hybridoma, 30(6):531-535 (2011).
  2. Kufe, DW. MUC1-C oncoprotein as a target in breast cancer: activation of signaling pathways and therapeutic approaches. Oncogene, 1-9 (2012).
  3. Kufe, DW. Mucins in cancer: function,prognosis and therapy. Nat Rev Cancer. 9(12):874-85 (2009).

If you publish research with this product, please let us know so we can cite your paper.

Loading...